nodes	percent_of_prediction	percent_of_DWPC	metapath
Medroxyprogesterone Acetate—uterine cancer—sarcoma	0.666	1	CtDrD
Medroxyprogesterone Acetate—AKR1C3—Doxorubicin—sarcoma	0.115	0.669	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Thiotepa—sarcoma	0.02	0.116	CbGbCtD
Medroxyprogesterone Acetate—CYP2C8—Etoposide—sarcoma	0.0134	0.0776	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Mitoxantrone—sarcoma	0.0086	0.0499	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Vincristine—sarcoma	0.00592	0.0343	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Etoposide—sarcoma	0.00542	0.0315	CbGbCtD
Medroxyprogesterone Acetate—AR—scrotum—sarcoma	0.00451	0.127	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—Doxorubicin—sarcoma	0.0037	0.0215	CbGbCtD
Medroxyprogesterone Acetate—SHBG—hindlimb—sarcoma	0.00214	0.0601	CbGeAlD
Medroxyprogesterone Acetate—ESR1—periosteum—sarcoma	0.00212	0.0595	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—Podofilox—Etoposide—sarcoma	0.00143	0.592	CbGdCrCtD
Medroxyprogesterone Acetate—AKR1C3—Vinblastine—Vincristine—sarcoma	0.000983	0.408	CbGdCrCtD
Medroxyprogesterone Acetate—HSD3B2—testis—sarcoma	0.00094	0.0264	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—myometrium—sarcoma	0.000843	0.0237	CbGeAlD
Medroxyprogesterone Acetate—PGR—mammary gland—sarcoma	0.000804	0.0226	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—seminal vesicle—sarcoma	0.000761	0.0214	CbGeAlD
Medroxyprogesterone Acetate—HSD3B2—lymph node—sarcoma	0.000681	0.0191	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—smooth muscle tissue—sarcoma	0.000637	0.0179	CbGeAlD
Medroxyprogesterone Acetate—ESR1—mammary gland—sarcoma	0.000629	0.0177	CbGeAlD
Medroxyprogesterone Acetate—PGR—myometrium—sarcoma	0.000571	0.016	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—cardiac atrium—sarcoma	0.00055	0.0154	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—uterus—sarcoma	0.000547	0.0154	CbGeAlD
Medroxyprogesterone Acetate—SHBG—hematopoietic system—sarcoma	0.000544	0.0153	CbGeAlD
Medroxyprogesterone Acetate—SHBG—connective tissue—sarcoma	0.000524	0.0147	CbGeAlD
Medroxyprogesterone Acetate—CYP2C8—mammary gland—sarcoma	0.000518	0.0146	CbGeAlD
Medroxyprogesterone Acetate—PGR—hematopoietic system—sarcoma	0.00049	0.0138	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—tendon—sarcoma	0.000479	0.0135	CbGeAlD
Medroxyprogesterone Acetate—PGR—connective tissue—sarcoma	0.000472	0.0133	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—bone marrow—sarcoma	0.000464	0.013	CbGeAlD
Medroxyprogesterone Acetate—CYP2C9—mammary gland—sarcoma	0.00046	0.0129	CbGeAlD
Medroxyprogesterone Acetate—AR—myometrium—sarcoma	0.000455	0.0128	CbGeAlD
Medroxyprogesterone Acetate—ESR1—myometrium—sarcoma	0.000446	0.0125	CbGeAlD
Medroxyprogesterone Acetate—PGR—smooth muscle tissue—sarcoma	0.000432	0.0121	CbGeAlD
Medroxyprogesterone Acetate—ESR1—embryo—sarcoma	0.000429	0.0121	CbGeAlD
Medroxyprogesterone Acetate—SHBG—uterus—sarcoma	0.000411	0.0115	CbGeAlD
Medroxyprogesterone Acetate—AR—seminal vesicle—sarcoma	0.000411	0.0115	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—testis—sarcoma	0.000397	0.0111	CbGeAlD
Medroxyprogesterone Acetate—AR—hematopoietic system—sarcoma	0.00039	0.011	CbGeAlD
Medroxyprogesterone Acetate—ESR1—hematopoietic system—sarcoma	0.000383	0.0108	CbGeAlD
Medroxyprogesterone Acetate—AR—connective tissue—sarcoma	0.000376	0.0106	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—liver—sarcoma	0.000375	0.0105	CbGeAlD
Medroxyprogesterone Acetate—PGR—uterus—sarcoma	0.00037	0.0104	CbGeAlD
Medroxyprogesterone Acetate—ESR1—connective tissue—sarcoma	0.000369	0.0104	CbGeAlD
Medroxyprogesterone Acetate—SHBG—bone marrow—sarcoma	0.000349	0.0098	CbGeAlD
Medroxyprogesterone Acetate—PGR—lymphoid tissue—sarcoma	0.000345	0.00969	CbGeAlD
Medroxyprogesterone Acetate—AR—smooth muscle tissue—sarcoma	0.000344	0.00966	CbGeAlD
Medroxyprogesterone Acetate—AR—skin of body—sarcoma	0.000339	0.00954	CbGeAlD
Medroxyprogesterone Acetate—ESR1—smooth muscle tissue—sarcoma	0.000338	0.00949	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—myometrium—sarcoma	0.000329	0.00925	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—embryo—sarcoma	0.000317	0.0089	CbGeAlD
Medroxyprogesterone Acetate—CYP2C8—hematopoietic system—sarcoma	0.000316	0.00887	CbGeAlD
Medroxyprogesterone Acetate—SHBG—testis—sarcoma	0.000298	0.00838	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—seminal vesicle—sarcoma	0.000298	0.00836	CbGeAlD
Medroxyprogesterone Acetate—AR—cardiac atrium—sarcoma	0.000296	0.00833	CbGeAlD
Medroxyprogesterone Acetate—AR—uterus—sarcoma	0.000295	0.00829	CbGeAlD
Medroxyprogesterone Acetate—ESR1—uterus—sarcoma	0.00029	0.00813	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—lymph node—sarcoma	0.000287	0.00808	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—hematopoietic system—sarcoma	0.000283	0.00795	CbGeAlD
Medroxyprogesterone Acetate—SHBG—liver—sarcoma	0.000282	0.00792	CbGeAlD
Medroxyprogesterone Acetate—CYP2C9—hematopoietic system—sarcoma	0.00028	0.00788	CbGeAlD
Medroxyprogesterone Acetate—AR—lymphoid tissue—sarcoma	0.000275	0.00772	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—connective tissue—sarcoma	0.000272	0.00765	CbGeAlD
Medroxyprogesterone Acetate—ESR1—lymphoid tissue—sarcoma	0.00027	0.00758	CbGeAlD
Medroxyprogesterone Acetate—PGR—testis—sarcoma	0.000269	0.00755	CbGeAlD
Medroxyprogesterone Acetate—AR—tendon—sarcoma	0.000258	0.00726	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—smooth muscle tissue—sarcoma	0.000249	0.007	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—skin of body—sarcoma	0.000246	0.00691	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—cardiac atrium—sarcoma	0.000215	0.00603	CbGeAlD
Medroxyprogesterone Acetate—AR—testis—sarcoma	0.000214	0.00601	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—hematopoietic system—sarcoma	0.000214	0.00601	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—uterus—sarcoma	0.000214	0.006	CbGeAlD
Medroxyprogesterone Acetate—ESR1—testis—sarcoma	0.00021	0.0059	CbGeAlD
Medroxyprogesterone Acetate—AR—liver—sarcoma	0.000202	0.00568	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—lymphoid tissue—sarcoma	0.000199	0.00559	CbGeAlD
Medroxyprogesterone Acetate—ESR1—liver—sarcoma	0.000199	0.00558	CbGeAlD
Medroxyprogesterone Acetate—PGR—lymph node—sarcoma	0.000195	0.00547	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—tendon—sarcoma	0.000187	0.00526	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—bone marrow—sarcoma	0.000181	0.00509	CbGeAlD
Medroxyprogesterone Acetate—CYP2C8—testis—sarcoma	0.000173	0.00486	CbGeAlD
Medroxyprogesterone Acetate—CYP2C8—liver—sarcoma	0.000164	0.0046	CbGeAlD
Medroxyprogesterone Acetate—AR—lymph node—sarcoma	0.000155	0.00436	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—testis—sarcoma	0.000155	0.00435	CbGeAlD
Medroxyprogesterone Acetate—ESR1—lymph node—sarcoma	0.000152	0.00428	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—liver—sarcoma	0.000147	0.00412	CbGeAlD
Medroxyprogesterone Acetate—CYP2C9—liver—sarcoma	0.000145	0.00408	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—lymph node—sarcoma	0.000112	0.00316	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—liver—sarcoma	0.000111	0.00311	CbGeAlD
Medroxyprogesterone Acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CCND1—sarcoma	7.2e-05	0.0026	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	7.2e-05	0.0026	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—sarcoma	7.19e-05	0.0026	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—ENO2—sarcoma	7.15e-05	0.00258	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CTNNB1—sarcoma	7.13e-05	0.00258	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Regulation of nuclear SMAD2/3 signaling—JUN—sarcoma	7.12e-05	0.00257	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—HBA1—sarcoma	7.11e-05	0.00257	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Adipogenesis—FOXO1—sarcoma	7.09e-05	0.00256	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling mediated by p38-alpha and p38-beta—TP53—sarcoma	7.08e-05	0.00256	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—ATF-2 transcription factor network—CCND1—sarcoma	7.08e-05	0.00256	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—ATF-2 transcription factor network—JUN—sarcoma	7.07e-05	0.00255	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Plasma membrane estrogen receptor signaling—KRAS—sarcoma	7.02e-05	0.00254	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—FUS—sarcoma	6.95e-05	0.00251	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Aryl Hydrocarbon Receptor—MYC—sarcoma	6.93e-05	0.0025	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Regulation of Androgen receptor activity—SRC—sarcoma	6.8e-05	0.00246	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Aryl Hydrocarbon Receptor—EGFR—sarcoma	6.78e-05	0.00245	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	6.75e-05	0.00244	CbGpPWpGaD
Medroxyprogesterone Acetate—Alanine aminotransferase increased—Doxorubicin—sarcoma	6.67e-05	0.000696	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Validated nuclear estrogen receptor alpha network—CCND1—sarcoma	6.63e-05	0.0024	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Validated nuclear estrogen receptor alpha network—JUN—sarcoma	6.62e-05	0.00239	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Androgen receptor signaling pathway—CCND1—sarcoma	6.62e-05	0.00239	CbGpPWpGaD
Medroxyprogesterone Acetate—Dysuria—Epirubicin—sarcoma	6.61e-05	0.000689	CcSEcCtD
Medroxyprogesterone Acetate—AR—Androgen receptor signaling pathway—JUN—sarcoma	6.6e-05	0.00239	CbGpPWpGaD
Medroxyprogesterone Acetate—Dizziness—Thiotepa—sarcoma	6.6e-05	0.000688	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal distension—Doxorubicin—sarcoma	6.58e-05	0.000686	CcSEcCtD
Medroxyprogesterone Acetate—Upper respiratory tract infection—Epirubicin—sarcoma	6.57e-05	0.000685	CcSEcCtD
Medroxyprogesterone Acetate—AR—Androgen receptor signaling pathway—CTNNB1—sarcoma	6.55e-05	0.00237	CbGpPWpGaD
Medroxyprogesterone Acetate—Influenza—Doxorubicin—sarcoma	6.54e-05	0.000682	CcSEcCtD
Medroxyprogesterone Acetate—Asthma—Doxorubicin—sarcoma	6.54e-05	0.000682	CcSEcCtD
Medroxyprogesterone Acetate—Dysphagia—Doxorubicin—sarcoma	6.54e-05	0.000682	CcSEcCtD
Medroxyprogesterone Acetate—Pollakiuria—Epirubicin—sarcoma	6.53e-05	0.000681	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Vincristine—sarcoma	6.52e-05	0.00068	CcSEcCtD
Medroxyprogesterone Acetate—PGR—Signaling by ERBB4—MDM2—sarcoma	6.5e-05	0.00235	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Regulation of Telomerase—IL2—sarcoma	6.48e-05	0.00234	CbGpPWpGaD
Medroxyprogesterone Acetate—Paraesthesia—Etoposide—sarcoma	6.44e-05	0.000671	CcSEcCtD
Medroxyprogesterone Acetate—Weight increased—Epirubicin—sarcoma	6.43e-05	0.000671	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Aryl Hydrocarbon Receptor—KRAS—sarcoma	6.4e-05	0.00231	CbGpPWpGaD
Medroxyprogesterone Acetate—Weight decreased—Epirubicin—sarcoma	6.39e-05	0.000667	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Etoposide—sarcoma	6.39e-05	0.000666	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—FOXO1—sarcoma	6.39e-05	0.00231	CbGpPWpGaD
Medroxyprogesterone Acetate—Hyperglycaemia—Epirubicin—sarcoma	6.37e-05	0.000665	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Etoposide—sarcoma	6.37e-05	0.000665	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—FOXO1—sarcoma	6.35e-05	0.0023	CbGpPWpGaD
Medroxyprogesterone Acetate—Hypersensitivity—Mitoxantrone—sarcoma	6.35e-05	0.000662	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Vincristine—sarcoma	6.35e-05	0.000662	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Thiotepa—sarcoma	6.34e-05	0.000662	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—PDGFRB—sarcoma	6.34e-05	0.00229	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—AP-1 transcription factor network—IL2—sarcoma	6.34e-05	0.00229	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Regulation of Telomerase—CCND1—sarcoma	6.32e-05	0.00228	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Regulation of Telomerase—JUN—sarcoma	6.31e-05	0.00228	CbGpPWpGaD
Medroxyprogesterone Acetate—Infestation NOS—Epirubicin—sarcoma	6.3e-05	0.000657	CcSEcCtD
Medroxyprogesterone Acetate—Infestation—Epirubicin—sarcoma	6.3e-05	0.000657	CcSEcCtD
Medroxyprogesterone Acetate—Drowsiness—Epirubicin—sarcoma	6.3e-05	0.000657	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Dactinomycin—sarcoma	6.3e-05	0.000657	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Thiotepa—sarcoma	6.29e-05	0.000656	CcSEcCtD
Medroxyprogesterone Acetate—Bronchitis—Doxorubicin—sarcoma	6.29e-05	0.000656	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Thiotepa—sarcoma	6.29e-05	0.000656	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Thiotepa—sarcoma	6.25e-05	0.000652	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Dactinomycin—sarcoma	6.24e-05	0.000651	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—PDGFRA—sarcoma	6.24e-05	0.00226	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—AP-1 transcription factor network—IL2—sarcoma	6.24e-05	0.00225	CbGpPWpGaD
Medroxyprogesterone Acetate—Decreased appetite—Etoposide—sarcoma	6.23e-05	0.00065	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Etoposide—sarcoma	6.19e-05	0.000645	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Mitoxantrone—sarcoma	6.18e-05	0.000645	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Etoposide—sarcoma	6.18e-05	0.000644	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—AP-1 transcription factor network—CCND1—sarcoma	6.18e-05	0.00223	CbGpPWpGaD
Medroxyprogesterone Acetate—Neuropathy peripheral—Epirubicin—sarcoma	6.18e-05	0.000644	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—Endoderm Differentiation—CTNNB1—sarcoma	6.16e-05	0.00223	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—AP-1 transcription factor network—JUN—sarcoma	6.16e-05	0.00223	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Glucocorticoid receptor regulatory network—MDM2—sarcoma	6.15e-05	0.00222	CbGpPWpGaD
Medroxyprogesterone Acetate—Stomatitis—Epirubicin—sarcoma	6.14e-05	0.00064	CcSEcCtD
Medroxyprogesterone Acetate—Jaundice—Epirubicin—sarcoma	6.14e-05	0.00064	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Etoposide—sarcoma	6.13e-05	0.000639	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract infection—Epirubicin—sarcoma	6.12e-05	0.000639	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—AP-1 transcription factor network—CTNNB1—sarcoma	6.12e-05	0.00221	CbGpPWpGaD
Medroxyprogesterone Acetate—Dysuria—Doxorubicin—sarcoma	6.11e-05	0.000638	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—AP-1 transcription factor network—CCND1—sarcoma	6.08e-05	0.0022	CbGpPWpGaD
Medroxyprogesterone Acetate—Upper respiratory tract infection—Doxorubicin—sarcoma	6.08e-05	0.000634	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—AP-1 transcription factor network—JUN—sarcoma	6.07e-05	0.00219	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—PLCG1—sarcoma	6.07e-05	0.00219	CbGpPWpGaD
Medroxyprogesterone Acetate—Diarrhoea—Vincristine—sarcoma	6.05e-05	0.000631	CcSEcCtD
Medroxyprogesterone Acetate—Sweating—Epirubicin—sarcoma	6.04e-05	0.00063	CcSEcCtD
Medroxyprogesterone Acetate—Pollakiuria—Doxorubicin—sarcoma	6.04e-05	0.00063	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—AP-1 transcription factor network—CTNNB1—sarcoma	6.02e-05	0.00218	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—CREB1—sarcoma	6.01e-05	0.00217	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—LKB1 signaling events—TP53—sarcoma	6.01e-05	0.00217	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Plasma membrane estrogen receptor signaling—HRAS—sarcoma	5.97e-05	0.00216	CbGpPWpGaD
Medroxyprogesterone Acetate—Hepatobiliary disease—Epirubicin—sarcoma	5.96e-05	0.000621	CcSEcCtD
Medroxyprogesterone Acetate—Weight increased—Doxorubicin—sarcoma	5.95e-05	0.00062	CcSEcCtD
Medroxyprogesterone Acetate—Epistaxis—Epirubicin—sarcoma	5.94e-05	0.00062	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Thiotepa—sarcoma	5.93e-05	0.000618	CcSEcCtD
Medroxyprogesterone Acetate—AR—Androgen receptor signaling pathway—SRC—sarcoma	5.92e-05	0.00214	CbGpPWpGaD
Medroxyprogesterone Acetate—Weight decreased—Doxorubicin—sarcoma	5.91e-05	0.000617	CcSEcCtD
Medroxyprogesterone Acetate—Sinusitis—Epirubicin—sarcoma	5.91e-05	0.000616	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Etoposide—sarcoma	5.91e-05	0.000616	CcSEcCtD
Medroxyprogesterone Acetate—Hyperglycaemia—Doxorubicin—sarcoma	5.9e-05	0.000615	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Mitoxantrone—sarcoma	5.9e-05	0.000615	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Dactinomycin—sarcoma	5.88e-05	0.000613	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Etoposide—sarcoma	5.86e-05	0.000611	CcSEcCtD
Medroxyprogesterone Acetate—AR—SIDS Susceptibility Pathways—CREB1—sarcoma	5.86e-05	0.00212	CbGpPWpGaD
Medroxyprogesterone Acetate—Dizziness—Vincristine—sarcoma	5.85e-05	0.00061	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Leptin signaling pathway—CCND1—sarcoma	5.84e-05	0.00211	CbGpPWpGaD
Medroxyprogesterone Acetate—Drowsiness—Doxorubicin—sarcoma	5.83e-05	0.000608	CcSEcCtD
Medroxyprogesterone Acetate—Infestation NOS—Doxorubicin—sarcoma	5.83e-05	0.000608	CcSEcCtD
Medroxyprogesterone Acetate—Infestation—Doxorubicin—sarcoma	5.83e-05	0.000608	CcSEcCtD
Medroxyprogesterone Acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—sarcoma	5.78e-05	0.00209	CbGpPWpGaD
Medroxyprogesterone Acetate—Bradycardia—Epirubicin—sarcoma	5.76e-05	0.0006	CcSEcCtD
Medroxyprogesterone Acetate—AR—Regulation of nuclear SMAD2/3 signaling—MYC—sarcoma	5.72e-05	0.00207	CbGpPWpGaD
Medroxyprogesterone Acetate—Neuropathy peripheral—Doxorubicin—sarcoma	5.71e-05	0.000596	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Etoposide—sarcoma	5.69e-05	0.000594	CcSEcCtD
Medroxyprogesterone Acetate—Haemoglobin—Epirubicin—sarcoma	5.68e-05	0.000593	CcSEcCtD
Medroxyprogesterone Acetate—Jaundice—Doxorubicin—sarcoma	5.68e-05	0.000593	CcSEcCtD
Medroxyprogesterone Acetate—Stomatitis—Doxorubicin—sarcoma	5.68e-05	0.000593	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Etoposide—sarcoma	5.67e-05	0.000591	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Etoposide—sarcoma	5.67e-05	0.000591	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract infection—Doxorubicin—sarcoma	5.67e-05	0.000591	CcSEcCtD
Medroxyprogesterone Acetate—Haemorrhage—Epirubicin—sarcoma	5.66e-05	0.00059	CcSEcCtD
Medroxyprogesterone Acetate—Hepatitis—Epirubicin—sarcoma	5.66e-05	0.00059	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Vincristine—sarcoma	5.63e-05	0.000587	CcSEcCtD
Medroxyprogesterone Acetate—Pharyngitis—Epirubicin—sarcoma	5.61e-05	0.000585	CcSEcCtD
Medroxyprogesterone Acetate—Sweating—Doxorubicin—sarcoma	5.59e-05	0.000583	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract disorder—Epirubicin—sarcoma	5.58e-05	0.000582	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Vincristine—sarcoma	5.58e-05	0.000582	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Vincristine—sarcoma	5.57e-05	0.000581	CcSEcCtD
Medroxyprogesterone Acetate—Oedema peripheral—Epirubicin—sarcoma	5.57e-05	0.000581	CcSEcCtD
Medroxyprogesterone Acetate—Connective tissue disorder—Epirubicin—sarcoma	5.56e-05	0.00058	CcSEcCtD
Medroxyprogesterone Acetate—Urethral disorder—Epirubicin—sarcoma	5.54e-05	0.000578	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Vincristine—sarcoma	5.54e-05	0.000578	CcSEcCtD
Medroxyprogesterone Acetate—Hepatobiliary disease—Doxorubicin—sarcoma	5.51e-05	0.000575	CcSEcCtD
Medroxyprogesterone Acetate—Epistaxis—Doxorubicin—sarcoma	5.5e-05	0.000573	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—Glucocorticoid receptor regulatory network—IL2—sarcoma	5.5e-05	0.00199	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Regulation of nuclear SMAD2/3 signaling—JUN—sarcoma	5.48e-05	0.00198	CbGpPWpGaD
Medroxyprogesterone Acetate—Vomiting—Mitoxantrone—sarcoma	5.48e-05	0.000571	CcSEcCtD
Medroxyprogesterone Acetate—Sinusitis—Doxorubicin—sarcoma	5.47e-05	0.00057	CcSEcCtD
Medroxyprogesterone Acetate—Visual impairment—Epirubicin—sarcoma	5.45e-05	0.000568	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Aryl Hydrocarbon Receptor—HRAS—sarcoma	5.44e-05	0.00197	CbGpPWpGaD
Medroxyprogesterone Acetate—Rash—Mitoxantrone—sarcoma	5.43e-05	0.000567	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Mitoxantrone—sarcoma	5.43e-05	0.000566	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—Regulation of nuclear SMAD2/3 signaling—JUN—sarcoma	5.4e-05	0.00195	CbGpPWpGaD
Medroxyprogesterone Acetate—Headache—Mitoxantrone—sarcoma	5.4e-05	0.000563	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Disease—TLE1—sarcoma	5.4e-05	0.00195	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Glucocorticoid receptor regulatory network—JUN—sarcoma	5.35e-05	0.00193	CbGpPWpGaD
Medroxyprogesterone Acetate—Erythema multiforme—Epirubicin—sarcoma	5.35e-05	0.000558	CcSEcCtD
Medroxyprogesterone Acetate—Bradycardia—Doxorubicin—sarcoma	5.33e-05	0.000556	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Validated nuclear estrogen receptor alpha network—MYC—sarcoma	5.32e-05	0.00192	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—FUS—sarcoma	5.3e-05	0.00191	CbGpPWpGaD
Medroxyprogesterone Acetate—Eye disorder—Epirubicin—sarcoma	5.28e-05	0.000551	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Etoposide—sarcoma	5.28e-05	0.000551	CcSEcCtD
Medroxyprogesterone Acetate—Tinnitus—Epirubicin—sarcoma	5.27e-05	0.00055	CcSEcCtD
Medroxyprogesterone Acetate—Haemoglobin—Doxorubicin—sarcoma	5.26e-05	0.000548	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Vincristine—sarcoma	5.26e-05	0.000548	CcSEcCtD
Medroxyprogesterone Acetate—Cardiac disorder—Epirubicin—sarcoma	5.25e-05	0.000547	CcSEcCtD
Medroxyprogesterone Acetate—Haemorrhage—Doxorubicin—sarcoma	5.23e-05	0.000546	CcSEcCtD
Medroxyprogesterone Acetate—Hepatitis—Doxorubicin—sarcoma	5.23e-05	0.000546	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Leptin signaling pathway—SRC—sarcoma	5.23e-05	0.00189	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	5.2e-05	0.00188	CbGpPWpGaD
Medroxyprogesterone Acetate—Pharyngitis—Doxorubicin—sarcoma	5.19e-05	0.000542	CcSEcCtD
Medroxyprogesterone Acetate—AR—Androgen receptor signaling pathway—EGFR—sarcoma	5.19e-05	0.00188	CbGpPWpGaD
Medroxyprogesterone Acetate—Urinary tract disorder—Doxorubicin—sarcoma	5.17e-05	0.000539	CcSEcCtD
Medroxyprogesterone Acetate—Oedema peripheral—Doxorubicin—sarcoma	5.15e-05	0.000538	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—Adipogenesis—CREB1—sarcoma	5.14e-05	0.00186	CbGpPWpGaD
Medroxyprogesterone Acetate—Asthenia—Etoposide—sarcoma	5.14e-05	0.000536	CcSEcCtD
Medroxyprogesterone Acetate—Connective tissue disorder—Doxorubicin—sarcoma	5.14e-05	0.000536	CcSEcCtD
Medroxyprogesterone Acetate—Angiopathy—Epirubicin—sarcoma	5.13e-05	0.000535	CcSEcCtD
Medroxyprogesterone Acetate—Urethral disorder—Doxorubicin—sarcoma	5.13e-05	0.000535	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Mitoxantrone—sarcoma	5.12e-05	0.000534	CcSEcCtD
Medroxyprogesterone Acetate—Immune system disorder—Epirubicin—sarcoma	5.11e-05	0.000533	CcSEcCtD
Medroxyprogesterone Acetate—Mediastinal disorder—Epirubicin—sarcoma	5.1e-05	0.000532	CcSEcCtD
Medroxyprogesterone Acetate—Chills—Epirubicin—sarcoma	5.07e-05	0.000529	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Etoposide—sarcoma	5.07e-05	0.000529	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Regulation of Telomerase—MYC—sarcoma	5.07e-05	0.00183	CbGpPWpGaD
Medroxyprogesterone Acetate—Visual impairment—Doxorubicin—sarcoma	5.04e-05	0.000526	CcSEcCtD
Medroxyprogesterone Acetate—Alopecia—Epirubicin—sarcoma	5e-05	0.000521	CcSEcCtD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	4.98e-05	0.0018	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—MDM2—sarcoma	4.98e-05	0.0018	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Regulation of Telomerase—EGFR—sarcoma	4.96e-05	0.00179	CbGpPWpGaD
Medroxyprogesterone Acetate—Mental disorder—Epirubicin—sarcoma	4.95e-05	0.000517	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—AP-1 transcription factor network—MYC—sarcoma	4.95e-05	0.00179	CbGpPWpGaD
Medroxyprogesterone Acetate—Erythema multiforme—Doxorubicin—sarcoma	4.95e-05	0.000516	CcSEcCtD
Medroxyprogesterone Acetate—Malnutrition—Epirubicin—sarcoma	4.92e-05	0.000513	CcSEcCtD
Medroxyprogesterone Acetate—Erythema—Epirubicin—sarcoma	4.92e-05	0.000513	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Etoposide—sarcoma	4.9e-05	0.000511	CcSEcCtD
Medroxyprogesterone Acetate—Eye disorder—Doxorubicin—sarcoma	4.89e-05	0.00051	CcSEcCtD
Medroxyprogesterone Acetate—Tinnitus—Doxorubicin—sarcoma	4.88e-05	0.000509	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—AP-1 transcription factor network—MYC—sarcoma	4.88e-05	0.00176	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling by ERBB4—NRAS—sarcoma	4.87e-05	0.00176	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—NPM1—sarcoma	4.87e-05	0.00176	CbGpPWpGaD
Medroxyprogesterone Acetate—Cardiac disorder—Doxorubicin—sarcoma	4.86e-05	0.000506	CcSEcCtD
Medroxyprogesterone Acetate—Flatulence—Epirubicin—sarcoma	4.85e-05	0.000506	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—KIT—sarcoma	4.84e-05	0.00175	CbGpPWpGaD
Medroxyprogesterone Acetate—Tension—Epirubicin—sarcoma	4.83e-05	0.000504	CcSEcCtD
Medroxyprogesterone Acetate—Dysgeusia—Epirubicin—sarcoma	4.82e-05	0.000503	CcSEcCtD
Medroxyprogesterone Acetate—Nervousness—Epirubicin—sarcoma	4.78e-05	0.000499	CcSEcCtD
Medroxyprogesterone Acetate—Back pain—Epirubicin—sarcoma	4.76e-05	0.000497	CcSEcCtD
Medroxyprogesterone Acetate—Angiopathy—Doxorubicin—sarcoma	4.75e-05	0.000495	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Etoposide—sarcoma	4.74e-05	0.000494	CcSEcCtD
Medroxyprogesterone Acetate—Muscle spasms—Epirubicin—sarcoma	4.73e-05	0.000494	CcSEcCtD
Medroxyprogesterone Acetate—Immune system disorder—Doxorubicin—sarcoma	4.73e-05	0.000493	CcSEcCtD
Medroxyprogesterone Acetate—Mediastinal disorder—Doxorubicin—sarcoma	4.72e-05	0.000492	CcSEcCtD
Medroxyprogesterone Acetate—Chills—Doxorubicin—sarcoma	4.7e-05	0.00049	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—CREB1—sarcoma	4.63e-05	0.00167	CbGpPWpGaD
Medroxyprogesterone Acetate—Alopecia—Doxorubicin—sarcoma	4.62e-05	0.000482	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—CREB1—sarcoma	4.61e-05	0.00167	CbGpPWpGaD
Medroxyprogesterone Acetate—Mental disorder—Doxorubicin—sarcoma	4.58e-05	0.000478	CcSEcCtD
Medroxyprogesterone Acetate—Ill-defined disorder—Epirubicin—sarcoma	4.57e-05	0.000476	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Etoposide—sarcoma	4.56e-05	0.000475	CcSEcCtD
Medroxyprogesterone Acetate—Malnutrition—Doxorubicin—sarcoma	4.56e-05	0.000475	CcSEcCtD
Medroxyprogesterone Acetate—Erythema—Doxorubicin—sarcoma	4.56e-05	0.000475	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Epirubicin—sarcoma	4.55e-05	0.000475	CcSEcCtD
Medroxyprogesterone Acetate—Agitation—Epirubicin—sarcoma	4.52e-05	0.000472	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Etoposide—sarcoma	4.52e-05	0.000471	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Etoposide—sarcoma	4.52e-05	0.000471	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Etoposide—sarcoma	4.49e-05	0.000468	CcSEcCtD
Medroxyprogesterone Acetate—Flatulence—Doxorubicin—sarcoma	4.49e-05	0.000468	CcSEcCtD
Medroxyprogesterone Acetate—Tension—Doxorubicin—sarcoma	4.47e-05	0.000466	CcSEcCtD
Medroxyprogesterone Acetate—Dysgeusia—Doxorubicin—sarcoma	4.46e-05	0.000465	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—SIDS Susceptibility Pathways—CREB1—sarcoma	4.45e-05	0.00161	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling by ERBB4—EGFR—sarcoma	4.44e-05	0.0016	CbGpPWpGaD
Medroxyprogesterone Acetate—Malaise—Epirubicin—sarcoma	4.44e-05	0.000463	CcSEcCtD
Medroxyprogesterone Acetate—Nervousness—Doxorubicin—sarcoma	4.42e-05	0.000461	CcSEcCtD
Medroxyprogesterone Acetate—Vertigo—Epirubicin—sarcoma	4.42e-05	0.000461	CcSEcCtD
Medroxyprogesterone Acetate—Syncope—Epirubicin—sarcoma	4.41e-05	0.00046	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Regulation of nuclear SMAD2/3 signaling—MYC—sarcoma	4.41e-05	0.00159	CbGpPWpGaD
Medroxyprogesterone Acetate—Back pain—Doxorubicin—sarcoma	4.41e-05	0.000459	CcSEcCtD
Medroxyprogesterone Acetate—Muscle spasms—Doxorubicin—sarcoma	4.38e-05	0.000457	CcSEcCtD
Medroxyprogesterone Acetate—Palpitations—Epirubicin—sarcoma	4.35e-05	0.000454	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—sarcoma	4.34e-05	0.00157	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—CCND1—sarcoma	4.33e-05	0.00157	CbGpPWpGaD
Medroxyprogesterone Acetate—Loss of consciousness—Epirubicin—sarcoma	4.33e-05	0.000451	CcSEcCtD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—JUN—sarcoma	4.32e-05	0.00156	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—CTNNB1—sarcoma	4.29e-05	0.00155	CbGpPWpGaD
Medroxyprogesterone Acetate—Convulsion—Epirubicin—sarcoma	4.27e-05	0.000445	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Etoposide—sarcoma	4.26e-05	0.000444	CcSEcCtD
Medroxyprogesterone Acetate—Ill-defined disorder—Doxorubicin—sarcoma	4.23e-05	0.000441	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Disease—ENO2—sarcoma	4.22e-05	0.00152	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—SIDS Susceptibility Pathways—JUN—sarcoma	4.21e-05	0.00152	CbGpPWpGaD
Medroxyprogesterone Acetate—Anaemia—Doxorubicin—sarcoma	4.21e-05	0.000439	CcSEcCtD
Medroxyprogesterone Acetate—PGR—Signaling by ERBB4—KRAS—sarcoma	4.19e-05	0.00152	CbGpPWpGaD
Medroxyprogesterone Acetate—Chest pain—Epirubicin—sarcoma	4.19e-05	0.000437	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Epirubicin—sarcoma	4.19e-05	0.000437	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Epirubicin—sarcoma	4.19e-05	0.000437	CcSEcCtD
Medroxyprogesterone Acetate—Agitation—Doxorubicin—sarcoma	4.19e-05	0.000437	CcSEcCtD
Medroxyprogesterone Acetate—AR—SIDS Susceptibility Pathways—CTNNB1—sarcoma	4.18e-05	0.00151	CbGpPWpGaD
Medroxyprogesterone Acetate—Anxiety—Epirubicin—sarcoma	4.18e-05	0.000436	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	4.16e-05	0.000434	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Epirubicin—sarcoma	4.14e-05	0.000432	CcSEcCtD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	4.12e-05	0.00149	CbGpPWpGaD
Medroxyprogesterone Acetate—Malaise—Doxorubicin—sarcoma	4.11e-05	0.000428	CcSEcCtD
Medroxyprogesterone Acetate—Dry mouth—Epirubicin—sarcoma	4.1e-05	0.000427	CcSEcCtD
Medroxyprogesterone Acetate—Vertigo—Doxorubicin—sarcoma	4.09e-05	0.000427	CcSEcCtD
Medroxyprogesterone Acetate—Syncope—Doxorubicin—sarcoma	4.08e-05	0.000426	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Gene Expression—FUS—sarcoma	4.08e-05	0.00147	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—AP-1 transcription factor network—TP53—sarcoma	4.07e-05	0.00147	CbGpPWpGaD
Medroxyprogesterone Acetate—Confusional state—Epirubicin—sarcoma	4.05e-05	0.000422	CcSEcCtD
Medroxyprogesterone Acetate—Palpitations—Doxorubicin—sarcoma	4.03e-05	0.00042	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—FUS—sarcoma	4.02e-05	0.00145	CbGpPWpGaD
Medroxyprogesterone Acetate—Anaphylactic shock—Epirubicin—sarcoma	4.02e-05	0.000419	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Epirubicin—sarcoma	4.02e-05	0.000419	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—AP-1 transcription factor network—TP53—sarcoma	4.01e-05	0.00145	CbGpPWpGaD
Medroxyprogesterone Acetate—Loss of consciousness—Doxorubicin—sarcoma	4e-05	0.000418	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Epirubicin—sarcoma	3.99e-05	0.000416	CcSEcCtD
Medroxyprogesterone Acetate—Shock—Epirubicin—sarcoma	3.95e-05	0.000412	CcSEcCtD
Medroxyprogesterone Acetate—Convulsion—Doxorubicin—sarcoma	3.95e-05	0.000412	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Epirubicin—sarcoma	3.94e-05	0.000411	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Epirubicin—sarcoma	3.93e-05	0.00041	CcSEcCtD
Medroxyprogesterone Acetate—Tachycardia—Epirubicin—sarcoma	3.92e-05	0.000409	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Epirubicin—sarcoma	3.9e-05	0.000407	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Epirubicin—sarcoma	3.88e-05	0.000405	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Doxorubicin—sarcoma	3.88e-05	0.000404	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Doxorubicin—sarcoma	3.88e-05	0.000404	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Doxorubicin—sarcoma	3.88e-05	0.000404	CcSEcCtD
Medroxyprogesterone Acetate—Anxiety—Doxorubicin—sarcoma	3.86e-05	0.000403	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	3.85e-05	0.000402	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	3.84e-05	0.00139	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—MDM2—sarcoma	3.83e-05	0.00138	CbGpPWpGaD
Medroxyprogesterone Acetate—Discomfort—Doxorubicin—sarcoma	3.83e-05	0.0004	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Epirubicin—sarcoma	3.83e-05	0.000399	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—MDM2—sarcoma	3.81e-05	0.00138	CbGpPWpGaD
Medroxyprogesterone Acetate—Dry mouth—Doxorubicin—sarcoma	3.79e-05	0.000396	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—TLE1—sarcoma	3.78e-05	0.00137	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—VEGFA—sarcoma	3.78e-05	0.00137	CbGpPWpGaD
Medroxyprogesterone Acetate—Hypotension—Epirubicin—sarcoma	3.75e-05	0.000392	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Doxorubicin—sarcoma	3.75e-05	0.000391	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Doxorubicin—sarcoma	3.72e-05	0.000388	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Doxorubicin—sarcoma	3.72e-05	0.000388	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Doxorubicin—sarcoma	3.69e-05	0.000385	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Leptin signaling pathway—HRAS—sarcoma	3.68e-05	0.00133	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—SIDS Susceptibility Pathways—VEGFA—sarcoma	3.68e-05	0.00133	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Adipogenesis—CTNNB1—sarcoma	3.67e-05	0.00133	CbGpPWpGaD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Epirubicin—sarcoma	3.66e-05	0.000382	CcSEcCtD
Medroxyprogesterone Acetate—Shock—Doxorubicin—sarcoma	3.66e-05	0.000381	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Doxorubicin—sarcoma	3.65e-05	0.00038	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Doxorubicin—sarcoma	3.64e-05	0.00038	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Epirubicin—sarcoma	3.63e-05	0.000379	CcSEcCtD
Medroxyprogesterone Acetate—Tachycardia—Doxorubicin—sarcoma	3.63e-05	0.000378	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Doxorubicin—sarcoma	3.61e-05	0.000377	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Epirubicin—sarcoma	3.61e-05	0.000376	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Doxorubicin—sarcoma	3.59e-05	0.000375	CcSEcCtD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	3.59e-05	0.0013	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	3.58e-05	0.00129	CbGpPWpGaD
Medroxyprogesterone Acetate—Dyspnoea—Epirubicin—sarcoma	3.58e-05	0.000374	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Disease—PLCG1—sarcoma	3.58e-05	0.00129	CbGpPWpGaD
Medroxyprogesterone Acetate—Somnolence—Epirubicin—sarcoma	3.57e-05	0.000372	CcSEcCtD
Medroxyprogesterone Acetate—PGR—Signaling by ERBB4—HRAS—sarcoma	3.56e-05	0.00129	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	3.56e-05	0.00128	CbGpPWpGaD
Medroxyprogesterone Acetate—Anorexia—Doxorubicin—sarcoma	3.54e-05	0.00037	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Epirubicin—sarcoma	3.54e-05	0.000369	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—ENO2—sarcoma	3.53e-05	0.00128	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Glucocorticoid receptor regulatory network—TP53—sarcoma	3.53e-05	0.00128	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—HBA1—sarcoma	3.51e-05	0.00127	CbGpPWpGaD
Medroxyprogesterone Acetate—Decreased appetite—Epirubicin—sarcoma	3.49e-05	0.000364	CcSEcCtD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—MYC—sarcoma	3.48e-05	0.00126	CbGpPWpGaD
Medroxyprogesterone Acetate—Hypotension—Doxorubicin—sarcoma	3.47e-05	0.000362	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Epirubicin—sarcoma	3.47e-05	0.000362	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Epirubicin—sarcoma	3.46e-05	0.000361	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Disease—CXCR4—sarcoma	3.44e-05	0.00124	CbGpPWpGaD
Medroxyprogesterone Acetate—Constipation—Epirubicin—sarcoma	3.44e-05	0.000358	CcSEcCtD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—EGFR—sarcoma	3.4e-05	0.00123	CbGpPWpGaD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Doxorubicin—sarcoma	3.39e-05	0.000353	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Doxorubicin—sarcoma	3.36e-05	0.000351	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—CCND1—sarcoma	3.34e-05	0.00121	CbGpPWpGaD
Medroxyprogesterone Acetate—Paraesthesia—Doxorubicin—sarcoma	3.34e-05	0.000348	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—JUN—sarcoma	3.33e-05	0.0012	CbGpPWpGaD
Medroxyprogesterone Acetate—Dyspnoea—Doxorubicin—sarcoma	3.31e-05	0.000346	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Epirubicin—sarcoma	3.31e-05	0.000345	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—CTNNB1—sarcoma	3.31e-05	0.00119	CbGpPWpGaD
Medroxyprogesterone Acetate—Somnolence—Doxorubicin—sarcoma	3.3e-05	0.000345	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Epirubicin—sarcoma	3.29e-05	0.000343	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Doxorubicin—sarcoma	3.27e-05	0.000341	CcSEcCtD
Medroxyprogesterone Acetate—CYP3A4—Tryptophan metabolism—MDM2—sarcoma	3.23e-05	0.00117	CbGpPWpGaD
Medroxyprogesterone Acetate—Decreased appetite—Doxorubicin—sarcoma	3.23e-05	0.000337	CcSEcCtD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	3.21e-05	0.00116	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—KRAS—sarcoma	3.21e-05	0.00116	CbGpPWpGaD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Doxorubicin—sarcoma	3.21e-05	0.000335	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Doxorubicin—sarcoma	3.21e-05	0.000334	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—SIDS Susceptibility Pathways—JUN—sarcoma	3.2e-05	0.00116	CbGpPWpGaD
Medroxyprogesterone Acetate—Urticaria—Epirubicin—sarcoma	3.19e-05	0.000333	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—VEGFC—sarcoma	3.19e-05	0.00115	CbGpPWpGaD
Medroxyprogesterone Acetate—Constipation—Doxorubicin—sarcoma	3.18e-05	0.000332	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Epirubicin—sarcoma	3.18e-05	0.000331	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Epirubicin—sarcoma	3.18e-05	0.000331	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	3.18e-05	0.00115	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—SIDS Susceptibility Pathways—CTNNB1—sarcoma	3.17e-05	0.00115	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	3.13e-05	0.00113	CbGpPWpGaD
Medroxyprogesterone Acetate—Feeling abnormal—Doxorubicin—sarcoma	3.06e-05	0.000319	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Doxorubicin—sarcoma	3.04e-05	0.000317	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—PLCG1—sarcoma	3e-05	0.00108	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—TLE1—sarcoma	2.98e-05	0.00108	CbGpPWpGaD
Medroxyprogesterone Acetate—Hypersensitivity—Epirubicin—sarcoma	2.96e-05	0.000309	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Doxorubicin—sarcoma	2.95e-05	0.000308	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Doxorubicin—sarcoma	2.94e-05	0.000306	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Doxorubicin—sarcoma	2.94e-05	0.000306	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—VEGFA—sarcoma	2.91e-05	0.00105	CbGpPWpGaD
Medroxyprogesterone Acetate—Asthenia—Epirubicin—sarcoma	2.88e-05	0.000301	CcSEcCtD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	2.88e-05	0.00104	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—NRAS—sarcoma	2.86e-05	0.00103	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—TP53—sarcoma	2.85e-05	0.00103	CbGpPWpGaD
Medroxyprogesterone Acetate—Pruritus—Epirubicin—sarcoma	2.84e-05	0.000296	CcSEcCtD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	2.82e-05	0.00102	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—SIDS Susceptibility Pathways—VEGFA—sarcoma	2.79e-05	0.00101	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	2.77e-05	0.001	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	2.76e-05	0.000997	CbGpPWpGaD
Medroxyprogesterone Acetate—Diarrhoea—Epirubicin—sarcoma	2.75e-05	0.000287	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	2.74e-05	0.00099	CbGpPWpGaD
Medroxyprogesterone Acetate—Hypersensitivity—Doxorubicin—sarcoma	2.74e-05	0.000286	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—MYC—sarcoma	2.68e-05	0.000968	CbGpPWpGaD
Medroxyprogesterone Acetate—Asthenia—Doxorubicin—sarcoma	2.67e-05	0.000278	CcSEcCtD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	2.66e-05	0.000962	CbGpPWpGaD
Medroxyprogesterone Acetate—Dizziness—Epirubicin—sarcoma	2.66e-05	0.000277	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Doxorubicin—sarcoma	2.63e-05	0.000274	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—EGFR—sarcoma	2.62e-05	0.000946	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—EGFR—sarcoma	2.61e-05	0.000941	CbGpPWpGaD
Medroxyprogesterone Acetate—Vomiting—Epirubicin—sarcoma	2.55e-05	0.000266	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—FLT1—sarcoma	2.55e-05	0.000921	CbGpPWpGaD
Medroxyprogesterone Acetate—Diarrhoea—Doxorubicin—sarcoma	2.54e-05	0.000265	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Disease—FOXO1—sarcoma	2.54e-05	0.000917	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—PDGFRB—sarcoma	2.53e-05	0.000916	CbGpPWpGaD
Medroxyprogesterone Acetate—Rash—Epirubicin—sarcoma	2.53e-05	0.000264	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Epirubicin—sarcoma	2.53e-05	0.000264	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Epirubicin—sarcoma	2.52e-05	0.000262	CcSEcCtD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—VEGFC—sarcoma	2.52e-05	0.000909	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—PLCG1—sarcoma	2.51e-05	0.000905	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—PDGFRA—sarcoma	2.49e-05	0.000901	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	2.48e-05	0.000895	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—KRAS—sarcoma	2.47e-05	0.000894	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—KRAS—sarcoma	2.46e-05	0.000889	CbGpPWpGaD
Medroxyprogesterone Acetate—Dizziness—Doxorubicin—sarcoma	2.46e-05	0.000256	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	2.41e-05	0.000871	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CXCR4—sarcoma	2.41e-05	0.00087	CbGpPWpGaD
Medroxyprogesterone Acetate—Nausea—Epirubicin—sarcoma	2.39e-05	0.000249	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—ATF1—sarcoma	2.38e-05	0.00086	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	2.37e-05	0.000855	CbGpPWpGaD
Medroxyprogesterone Acetate—Vomiting—Doxorubicin—sarcoma	2.36e-05	0.000246	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Doxorubicin—sarcoma	2.34e-05	0.000244	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Doxorubicin—sarcoma	2.34e-05	0.000244	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Doxorubicin—sarcoma	2.33e-05	0.000243	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	2.22e-05	0.000802	CbGpPWpGaD
Medroxyprogesterone Acetate—Nausea—Doxorubicin—sarcoma	2.21e-05	0.00023	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—TP53—sarcoma	2.2e-05	0.000795	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	2.17e-05	0.000784	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—HRAS—sarcoma	2.09e-05	0.000756	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	2.05e-05	0.000741	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—FLT1—sarcoma	2.01e-05	0.000726	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PLCG1—sarcoma	1.98e-05	0.000714	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—KIT—sarcoma	1.93e-05	0.000699	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CXCR4—sarcoma	1.9e-05	0.000686	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Generic Transcription Pathway—MYC—sarcoma	1.88e-05	0.000679	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—ATF1—sarcoma	1.88e-05	0.000678	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—IGF1R—sarcoma	1.87e-05	0.000675	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—CREB1—sarcoma	1.84e-05	0.000665	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	1.82e-05	0.000658	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—FOXO1—sarcoma	1.78e-05	0.000642	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—PDGFRB—sarcoma	1.77e-05	0.000641	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—TLE1—sarcoma	1.75e-05	0.000632	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—PDGFRA—sarcoma	1.75e-05	0.000631	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—MDM2—sarcoma	1.52e-05	0.00055	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—VEGFC—sarcoma	1.48e-05	0.000533	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—IGF1R—sarcoma	1.47e-05	0.000532	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—KDR—sarcoma	1.47e-05	0.000531	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Generic Transcription Pathway—MYC—sarcoma	1.43e-05	0.000517	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—FOXO1—sarcoma	1.4e-05	0.000507	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PDGFRB—sarcoma	1.4e-05	0.000506	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PDGFRA—sarcoma	1.38e-05	0.000498	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—KIT—sarcoma	1.35e-05	0.000489	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—CTNNB1—sarcoma	1.31e-05	0.000475	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CREB1—sarcoma	1.29e-05	0.000466	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—SRC—sarcoma	1.19e-05	0.000429	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—FLT1—sarcoma	1.18e-05	0.000426	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—KDR—sarcoma	1.16e-05	0.000419	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PLCG1—sarcoma	1.16e-05	0.000419	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—NRAS—sarcoma	1.14e-05	0.000413	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CXCR4—sarcoma	1.11e-05	0.000403	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Generic Transcription Pathway—MYC—sarcoma	1.1e-05	0.000398	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—ATF1—sarcoma	1.1e-05	0.000398	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Generic Transcription Pathway—MYC—sarcoma	1.09e-05	0.000392	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—KIT—sarcoma	1.07e-05	0.000386	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—MDM2—sarcoma	1.07e-05	0.000385	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—MYC—sarcoma	1.06e-05	0.000385	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—EGFR—sarcoma	1.04e-05	0.000376	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CREB1—sarcoma	1.02e-05	0.000367	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—ENO2—sarcoma	9.93e-06	0.000359	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—HBA1—sarcoma	9.87e-06	0.000356	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—KRAS—sarcoma	9.83e-06	0.000355	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—IL2—sarcoma	9.53e-06	0.000344	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CCND1—sarcoma	9.29e-06	0.000336	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—JUN—sarcoma	9.27e-06	0.000335	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CTNNB1—sarcoma	9.2e-06	0.000332	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—MYC—sarcoma	9.04e-06	0.000327	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—IGF1R—sarcoma	8.65e-06	0.000312	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PLCG1—sarcoma	8.42e-06	0.000304	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—MDM2—sarcoma	8.42e-06	0.000304	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—HRAS—sarcoma	8.36e-06	0.000302	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—SRC—sarcoma	8.32e-06	0.000301	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—FOXO1—sarcoma	8.23e-06	0.000297	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PDGFRB—sarcoma	8.22e-06	0.000297	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—VEGFA—sarcoma	8.1e-06	0.000293	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PDGFRA—sarcoma	8.09e-06	0.000292	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—ENO2—sarcoma	8.08e-06	0.000292	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—HBA1—sarcoma	8.03e-06	0.00029	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—NRAS—sarcoma	8e-06	0.000289	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—IL2—sarcoma	7.52e-06	0.000272	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—MYC—sarcoma	7.45e-06	0.000269	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CCND1—sarcoma	7.33e-06	0.000265	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—JUN—sarcoma	7.31e-06	0.000264	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—EGFR—sarcoma	7.29e-06	0.000263	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CTNNB1—sarcoma	7.26e-06	0.000262	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—MYC—sarcoma	6.89e-06	0.000249	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—KRAS—sarcoma	6.89e-06	0.000249	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PLCG1—sarcoma	6.86e-06	0.000248	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—KDR—sarcoma	6.81e-06	0.000246	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—SRC—sarcoma	6.56e-06	0.000237	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—VEGFA—sarcoma	6.39e-06	0.000231	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—NRAS—sarcoma	6.31e-06	0.000228	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—KIT—sarcoma	6.27e-06	0.000227	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—TP53—sarcoma	6.12e-06	0.000221	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CREB1—sarcoma	5.97e-06	0.000216	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—MYC—sarcoma	5.88e-06	0.000212	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—HRAS—sarcoma	5.85e-06	0.000212	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—EGFR—sarcoma	5.75e-06	0.000208	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—KRAS—sarcoma	5.43e-06	0.000196	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ENO2—sarcoma	5.33e-06	0.000193	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—MYC—sarcoma	5.31e-06	0.000192	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—HBA1—sarcoma	5.3e-06	0.000191	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—MYC—sarcoma	5.23e-06	0.000189	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—MDM2—sarcoma	4.94e-06	0.000178	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—TP53—sarcoma	4.83e-06	0.000174	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—HRAS—sarcoma	4.62e-06	0.000167	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PLCG1—sarcoma	4.52e-06	0.000163	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—IL2—sarcoma	4.41e-06	0.000159	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CCND1—sarcoma	4.3e-06	0.000155	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—JUN—sarcoma	4.29e-06	0.000155	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CTNNB1—sarcoma	4.26e-06	0.000154	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—SRC—sarcoma	3.85e-06	0.000139	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—VEGFA—sarcoma	3.75e-06	0.000136	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—NRAS—sarcoma	3.7e-06	0.000134	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—MYC—sarcoma	3.45e-06	0.000125	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—EGFR—sarcoma	3.38e-06	0.000122	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—KRAS—sarcoma	3.19e-06	0.000115	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—TP53—sarcoma	2.83e-06	0.000102	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—HRAS—sarcoma	2.71e-06	9.79e-05	CbGpPWpGaD
